It can begin with symptoms that seem remarkably ordinary. A fever, a headache, muscle pain and overwhelming tiredness may initially resemble influenza or another common infection. Within days, however, an Ebola infection can develop into a life-threatening illness involving severe dehydration, circulatory shock and organ failure.
That danger has become particularly relevant in 2026, as a major Ebola outbreak continues to affect the Democratic Republic of the Congo and has been linked to cases in several other countries.
According to the US Centers for Disease Control and Prevention's October 20, 2026 update, the outbreak had reached 9,668 confirmed cases and 4,649 confirmed deaths across affected countries. The agency describes it as the second-largest Ebola outbreak ever recorded.
The outbreak is caused by Bundibugyo virus, one of several viruses responsible for Ebola disease. Unlike the Ebola virus responsible for the devastating West African epidemic of 2014–2016, the Bundibugyo virus has no specifically approved vaccine or antiviral treatment.
Also read: Explained: Mosquito-borne disease that turns deadly as fever disappears
Understanding the differences between these viruses, how transmission occurs and what doctors can do to improve survival is essential to understanding the current emergency.
What exactly is Ebola, and where does it come from?
Ebola is a severe infectious disease caused by viruses belonging to the genus Orthoebolavirus. It was previously widely known as Ebola haemorrhagic fever, although that description can be misleading because not everyone who develops the disease experiences bleeding.
The disease was first recognised in 1976, when two separate outbreaks occurred in Central Africa. One was identified in what is now South Sudan, while another occurred near the Ebola River in the territory now known as the Democratic Republic of the Congo. The river gave the disease its name.
According to the World Health Organization's Ebola factsheet, several related viruses can cause Ebola disease, but three have been responsible for major outbreaks: Ebola virus, historically known as Zaire ebolavirus; Sudan virus; and Bundibugyo virus.
Also read: Daily vitamin C cut deaths nearly in half in a randomized blood cancer trial
The distinction is important because these viruses differ in their historical fatality rates and, crucially, in the medical tools available to fight them. Vaccines and monoclonal antibody treatments developed for the Ebola virus are not automatically proven effective against the other species.
How do people become infected with Ebola?
Scientists believe African fruit bats may act as natural reservoirs for the viruses that cause Ebola, although the precise origins of individual outbreaks are not always established. Infections can pass from animals to humans when people come into close contact with infected blood, bodily fluids or tissues.
Potential sources include infected bats, monkeys, chimpanzees, gorillas and certain forest animals. Hunting, handling animal carcasses or preparing infected wildlife for food can create opportunities for transmission, particularly when blood or other bodily fluids come into contact with broken skin or mucous membranes.
Once the virus enters a human population, however, the main concern becomes transmission between people. A single infected individual can unintentionally expose family members, caregivers or healthcare workers, particularly when the illness has not yet been recognised and suitable precautions are not being used.
Also read: Half a million heart deaths a year come down to one number most people never check
Ebola is not transmitted by mosquitoes, unlike malaria or dengue fever. There is also no evidence that it spreads through ordinary airborne transmission in the manner of influenza, measles or COVID-19.
How does Ebola spread from one person to another?
Ebola spreads primarily through direct contact with the blood or other bodily fluids of someone who is sick with the disease or has died from it. These fluids can include vomit, diarrhoea, urine, saliva, sweat, breast milk and blood. Infection occurs when the virus enters through broken skin or the mucous membranes of the eyes, nose or mouth.
Objects contaminated with infected bodily fluids can also transmit the virus. Clothing, bedding, medical equipment and needles can become dangerous if they are handled without adequate protection or appropriate cleaning and disinfection.
The CDC's updated explanation of Ebola transmission makes an important distinction: people do not ordinarily transmit Ebola before developing symptoms. This means that being near someone who has been infected but is still in the symptom-free incubation period does not carry the same risk as direct exposure to an ill patient's bodily fluids.
Also read: FDA clears a drug that lets some rectal cancer patients skip surgery entirely
Funeral practices can also contribute to outbreaks. The body of someone who has died from Ebola remains infectious, and washing, touching or preparing it for burial without appropriate precautions can expose multiple people. Safe and dignified burial procedures are therefore an important part of outbreak control.
How long does it take for Ebola symptoms to appear?
The incubation period for Ebola ranges from two to 21 days, although symptoms most commonly begin approximately eight to ten days after exposure. During this period, the virus is multiplying inside the body, but the infected person generally feels well and is not contagious.
The first symptoms often appear suddenly. They commonly include high fever, extreme fatigue, headache, muscle and joint pain, sore throat and loss of appetite. Because these symptoms are not specific to Ebola, the illness may initially be mistaken for malaria, influenza, typhoid fever or another infectious disease.
According to the CDC's clinical description of Ebola symptoms, patients can develop more serious gastrointestinal symptoms after approximately four to five days of illness. These may include persistent vomiting, severe diarrhoea and abdominal pain, often accompanied by worsening weakness and substantial fluid loss.
Also read: One reading during your sleep study could flag your heart failure risk a decade early
Additional symptoms can include skin rashes, red eyes, confusion, difficulty breathing and, in some cases, seizures. Some patients experience bleeding from the gums or nose, blood in vomit or stool, or bleeding around injection sites. Nevertheless, bleeding is not universal, and its absence does not rule out Ebola.
What makes Ebola so dangerous inside the body?
As Ebola progresses, the virus can interfere with the immune response and damage tissues involved in regulating inflammation, circulation and organ function. Severe gastrointestinal symptoms may cause rapid losses of water and essential electrolytes, making it increasingly difficult for the body to maintain adequate blood pressure and circulation.
In critically ill patients, circulation can deteriorate into shock. The liver and kidneys may begin to fail, while disturbances in the body's clotting system can contribute to bleeding and other complications. Some patients develop severe neurological symptoms, including confusion or reduced consciousness.
Unlike a routine viral infection that usually improves with rest and time, severe Ebola can deteriorate rapidly without medical intervention. Patients may require intensive monitoring, intravenous fluids, treatment of metabolic disturbances and support for failing organs.
The severity of the illness also explains why delays in diagnosis can have such serious consequences. Someone who initially believes they have malaria or another common fever may not receive appropriate treatment until the disease has already reached an advanced stage.
Who is most likely to catch Ebola?
Ebola can infect people of any age or sex, but exposure is not evenly distributed. During an outbreak, the people at greatest risk are generally those who come into direct contact with infected patients, their bodily fluids or the bodies of people who have died from the disease.
According to the WHO's guidance on Ebola risk groups, healthcare workers, family caregivers and people participating in funeral rituals involving physical contact with the deceased face particularly significant risks when suitable protective measures are not followed.
Healthcare workers may be exposed while inserting intravenous lines, examining patients, cleaning contaminated equipment or treating someone whose infection has not yet been recognised. Family members can face similar dangers when providing intimate care at home, particularly during vomiting, diarrhoea or other stages involving contact with bodily fluids.
People handling infected wildlife are another potential risk group. However, living in an African country where outbreaks have previously occurred does not automatically place someone at high risk. The likelihood of infection depends heavily on whether the person has a meaningful exposure to the virus.
Why are young children and pregnant women a particular concern?
One of the most troubling findings from the current outbreak concerns children younger than five years old. While adults account for most reported cases, young children have experienced particularly high death rates.
In a September 21, 2026 report from WHO's African regional office, children under five were reported to have a case-fatality ratio exceeding 60%, compared with approximately 40% among adults at that stage of the outbreak.
Young children can become dehydrated quickly and may have less physiological reserve to withstand shock or major disturbances in blood glucose and electrolytes. Providing appropriate treatment also requires specialised equipment, medication doses and clinical expertise that may be difficult to access in remote outbreak areas.
Pregnancy presents a different set of concerns. Ebola infection can increase the risk of miscarriage, pregnancy-related bleeding, fetal loss and other serious obstetric complications. However, the CDC's guidance on Ebola in pregnancy notes that more recent research has not consistently found a higher maternal death rate than among non-pregnant patients.
Pregnant patients with suspected or confirmed Ebola require specialised hospital care, both because of the potential consequences for the pregnancy and because childbirth and pregnancy-related bodily fluids can create additional infection-control challenges.
Which countries have been most affected by Ebola?
Ebola outbreaks have occurred predominantly in sub-Saharan Africa, particularly in Central and parts of West Africa. The Democratic Republic of the Congo has experienced numerous outbreaks since 1976, while Uganda, Gabon, the Republic of the Congo and South Sudan have also recorded significant transmission.
Other countries affected by previous outbreaks include Guinea, Liberia, Sierra Leone and Côte d'Ivoire. Ebola does not circulate continuously throughout all these countries. Instead, outbreaks emerge at particular times and locations, followed by periods in which transmission is interrupted.
The most devastating historical epidemic occurred in West Africa between 2014 and 2016. According to the WHO's historical overview, the epidemic began in Guinea and spread extensively through Liberia and Sierra Leone, eventually resulting in more than 28,600 cases and 11,325 deaths.
That epidemic also demonstrated that Ebola could reach major cities and cross international borders. Cases were detected in countries outside the principal outbreak area, including Nigeria, Mali, Senegal, Spain, Italy, the United Kingdom and the United States, although the overwhelming majority of infections occurred in West Africa.
The 2026 Ebola outbreak is now the second-largest ever recorded
The current outbreak began in the Democratic Republic of the Congo in May 2026, when health authorities investigated clusters of severe illness and unusual deaths in Ituri Province. Laboratory testing confirmed Bundibugyo virus, and the country declared an outbreak on May 15.
Two days later, on May 17, WHO designated the outbreak a public health emergency of international concern. This designation reflects the international significance of the emergency and the need for coordinated measures to prevent further transmission.
The outbreak expanded rapidly across eastern and northeastern parts of the country. Ituri has remained the principal centre of transmission, with North Kivu also heavily affected. By October, cases had been detected across eight provinces, including Haut-Uélé, Tshopo, Bas-Uélé, South Kivu, South Ubangi and North Ubangi.
The European Centre for Disease Prevention and Control's October 20 update reported 9,552 confirmed infections and 4,602 deaths in the Democratic Republic of the Congo using national data available through October 19. Subsequent CDC figures placed the country's confirmed totals at 9,637 infections and 4,646 deaths.
The outbreak has also produced infections beyond the Democratic Republic of the Congo. Uganda reported 20 confirmed cases and two confirmed deaths before its outbreak was declared over in August. In October, Kenya identified a fatal imported case, followed by additional cases among close contacts and healthcare workers.
On October 20, WHO confirmed an imported case in Nigeria, involving a woman who had recently travelled from Uganda. Authorities began monitoring identified contacts while investigating her possible exposure.
Imported cases associated with the outbreak have also been treated in Europe, including France and medical evacuations to specialised hospitals in other countries. These cases highlight the potential for international movement of the virus, but they do not indicate widespread community transmission in Europe.
Why has the outbreak been so difficult to control?
Containing Ebola requires more than identifying the virus. Health authorities must rapidly find infected patients, provide safe medical care, identify their contacts and monitor potentially exposed people for the full 21-day incubation period.
This becomes considerably harder in remote areas with limited roads, disrupted communications and inadequate healthcare infrastructure. Patients may have to travel long distances to reach a properly equipped treatment facility, while laboratory results and the transport of medical supplies can be delayed.
According to the WHO's October 8 outbreak assessment, substantial numbers of deaths were occurring outside Ebola treatment centres, indicating that many patients were not being identified or reaching appropriate care quickly enough.
Armed conflict and insecurity have created additional difficulties in parts of the affected region. Medical teams may struggle to reach communities, maintain regular contact tracing or work safely in areas experiencing violence and population displacement.
Frequent travel between communities and across borders also complicates surveillance. When people become ill while travelling, health authorities may need to trace contacts across several countries, making cooperation between national healthcare systems essential.
How dangerous is Ebola for people living in Europe?
Despite the severity of the African outbreak, Ebola currently poses a very low risk to the general European population. Unlike respiratory infections, it does not spread simply because people share the same room, travel on the same street or pass one another in public spaces.
The ECDC's assessment of the current outbreak states that the overall risk to people living in Europe remains very low. Although imported infections can occur, European healthcare systems have specialised isolation facilities, infection-control procedures and surveillance arrangements designed to prevent further transmission.
Healthcare and humanitarian workers returning from affected areas face a different risk profile because their professional activities may involve direct exposure to infected patients. Even among these groups, appropriate protective equipment and infection-control procedures substantially reduce the likelihood of infection.
For ordinary travellers, the most important considerations are the destination and the activities undertaken. Someone who has no contact with infected individuals, infectious bodily fluids or potentially infected wildlife faces a much lower risk than a person providing direct care during an active outbreak.
How do doctors diagnose Ebola?
Diagnosing Ebola can be challenging because its early symptoms overlap with several much more common infectious diseases. Malaria, typhoid fever, dengue and certain bacterial infections can produce fever, weakness and gastrointestinal symptoms that resemble the beginning of Ebola.
Doctors therefore consider the patient's symptoms alongside travel history and possible exposure to infected individuals or animals. A person who has recently visited an Ebola-affected area and develops a compatible illness requires careful assessment, but fever alone does not establish an Ebola diagnosis.
Laboratory testing is essential. Reverse transcription polymerase chain reaction testing, commonly known as RT-PCR, can detect viral genetic material in blood samples. Other specialised tests can detect viral antigens or antibodies, depending on the circumstances and stage of infection.
The CDC's clinical guidance updated in May 2026 stresses that suspected Ebola patients must be assessed using appropriate infection-control precautions. Healthcare workers should also investigate other likely illnesses, particularly malaria, rather than delaying potentially lifesaving treatment while awaiting Ebola test results.
Is there a cure for Ebola?
Medical progress has substantially improved the treatment of certain Ebola infections, but an important limitation remains: not every virus responsible for Ebola disease has an approved targeted treatment.
The cornerstone of care is early, intensive supportive treatment. This can involve intravenous fluid replacement, correcting electrolyte imbalances, maintaining blood pressure, treating shock, providing oxygen and monitoring kidney and liver function.
Doctors may also need to treat additional infections, including malaria or bacterial infections, and provide nutritional support or other intensive care interventions. These treatments do not directly eliminate the Ebola virus, but they help patients survive the physiological effects of the disease while their immune systems respond.
For Ebola virus disease caused specifically by the Ebola virus, historically known as the Zaire species, two monoclonal antibody treatments have received US regulatory approval. Inmazeb combines three antibodies, while Ebanga contains a single antibody called ansuvimab. Both were evaluated in clinical trials and improved survival compared with the relevant trial comparators.
These treatments work by targeting a protein on the virus and interfering with its ability to infect cells. However, their effectiveness against other Ebola-causing viruses has not been established.
That distinction is especially important in 2026. There is no approved virus-specific treatment for Bundibugyo virus, which means patients in the current outbreak depend on high-quality supportive care while experimental therapeutic approaches continue to be investigated.
Why can't existing Ebola vaccines simply stop this outbreak?
The development of effective Ebola vaccines marked an important achievement in infectious disease prevention. However, the vaccines currently authorised for use against Ebola virus disease were developed specifically for the Ebola virus species historically called Zaire ebolavirus.
Ervebo is a single-dose vaccine used to protect against disease caused by that virus. Another vaccine regimen, Zabdeno and Mvabea, uses two doses and has received authorisation in the European Union for protection against the same Ebola virus species.
According to the WHO's vaccination guidance published on September 9, 2026, there is no licensed vaccine specifically for Bundibugyo virus disease. Candidate vaccines are being investigated, but they must undergo clinical evaluation to demonstrate safety and effectiveness.
Researchers are also studying whether Ervebo could provide some protection against Bundibugyo virus. Animal research has produced encouraging indications, but sufficient evidence of protection in humans is not yet available. WHO therefore recommends that its use against Bundibugyo virus be conducted within research protocols.
This does not mean vaccination is ineffective against Ebola generally. Rather, it illustrates why identifying the precise virus responsible for an outbreak matters so much. A vaccine proven effective against one Ebola-causing virus cannot simply be assumed to provide the same protection against another.
What percentage of people die from Ebola?
Ebola is among the infectious diseases associated with the highest reported case-fatality rates during major outbreaks. However, there is no single death rate that applies to every outbreak or every infected patient.
According to WHO, the average case-fatality rate across previous Ebola outbreaks is approximately 50%, with reported rates ranging from around 25% to 90%. These differences reflect the virus involved, the characteristics of affected patients, the timing and quality of medical care, and the way cases and deaths are identified.
The 2014–2016 West African epidemic resulted in approximately 11,325 deaths among more than 28,600 reported cases, giving an overall case-fatality ratio close to 40%. By comparison, the Democratic Republic of the Congo's smaller Ebola outbreak in 2025 recorded 45 deaths among 64 confirmed and probable cases, corresponding to approximately 70%.
The 2026 Bundibugyo outbreak has had a reported fatality ratio of approximately 48%. Based on the CDC's October 20 figures of 9,668 confirmed cases and 4,649 confirmed deaths, the proportion is around 48.1%.
These figures represent deaths among reported cases, not the probability that any person exposed to Ebola will die. They also do not precisely establish the final outcome of every infected patient, particularly during an active outbreak when some people remain under treatment.
Access to medical care can make a substantial difference. Early identification, appropriate fluid management, treatment of complications and intensive clinical monitoring improve the likelihood of survival, even where no virus-specific medicine is available.
What happens to people who survive Ebola?
Recovering from the acute infection does not always mean an immediate return to normal health. Ebola survivors can experience complications lasting for months or longer, sometimes requiring continued medical treatment and rehabilitation.
According to the CDC's guidance on caring for Ebola survivors, long-term effects can include persistent fatigue, joint and muscle pain, headaches, memory problems, hearing difficulties and inflammation affecting the eyes. Some survivors develop serious visual complications, while others experience sleep disturbances, anxiety, depression or post-traumatic stress.
There is also an important medical distinction between recovering from the illness and eliminating every trace of infectious virus from the body. In some survivors, Ebola-related viruses can persist in areas partly protected from the immune system, including the eyes, central nervous system and reproductive tissues.
The virus can sometimes remain in semen after a male survivor has otherwise recovered, creating a risk of sexual transmission. WHO recommends appropriate counselling and semen testing until two consecutive negative results are obtained. Where testing is unavailable, male survivors are advised to practise safer sex for 12 months.
These precautions do not mean that Ebola survivors are generally dangerous to other people. Routine social contact after recovery does not carry the same risk as exposure to infectious bodily fluids, and survivors should not be subjected to unnecessary stigma or exclusion.
Can Ebola be prevented without vaccination?
Yes. Effective prevention depends primarily on interrupting the routes through which the virus spreads. During an outbreak, avoiding direct exposure to infected bodily fluids, contaminated equipment and the bodies of people who have died from Ebola is central to reducing transmission.
Healthcare facilities use specialised protective equipment, patient isolation, safe waste disposal, careful cleaning procedures and controlled handling of needles and other potentially contaminated materials. Proper training is essential because protective equipment must be used and removed correctly to prevent accidental exposure.
Within communities, prevention measures include recognising symptoms promptly, avoiding unprotected physical contact with suspected cases and seeking medical advice rather than providing high-risk care without adequate protection. Safe and dignified burial practices allow families to observe important cultural and religious traditions while reducing the danger of transmission.
Public health teams also use contact tracing to identify individuals who may have been exposed. Contacts are monitored for 21 days, allowing symptoms to be recognised quickly and potentially infected people to receive appropriate assessment before additional transmission occurs.
A country can generally declare an Ebola outbreak over after 42 days without a new case, measured from the point at which the last known patient's infection is no longer considered an active source of transmission. Surveillance often continues afterwards because further cases or rare re-emergence events remain possible.
What should someone do after possible Ebola exposure?
Anyone who has had a relevant exposure to Ebola and subsequently develops fever, severe weakness, vomiting, diarrhoea or another compatible symptom should seek urgent medical assessment. Early treatment is important both for improving the patient's chances of survival and for preventing additional infections.
People should contact healthcare services or the relevant public health authority before arriving at a medical facility whenever possible. This allows staff to arrange safe assessment and appropriate infection-control precautions rather than exposing other patients or healthcare workers unnecessarily.
A suspected exposure does not automatically mean someone has become infected. The risk depends on the type of contact, whether infectious bodily fluids were involved and whether suitable protective precautions were used. Public health authorities can assess those circumstances and determine whether monitoring, testing or other measures are necessary.
For people returning from affected regions, awareness of symptoms during the following 21 days is particularly important. Healthcare workers and other people with direct exposure may be subject to additional monitoring requirements based on their individual risk.
Why the 2026 outbreak demonstrates that Ebola remains a global concern
The current outbreak has exposed a major gap in the world's defences against Ebola. Vaccination programmes and targeted antibody treatments have transformed the outlook for disease caused by one Ebola virus species, but those advances cannot yet be relied upon to control an outbreak caused by Bundibugyo virus.
At the same time, the epidemic illustrates the influence of healthcare access, conflict, delayed diagnosis and cross-border movement on infectious disease control. Thousands of people have died in an outbreak concentrated in areas where identifying patients rapidly and delivering intensive care can be exceptionally difficult.
For the general population outside affected regions, Ebola remains a rare infection and the immediate risk is very low. For families, healthcare workers and communities experiencing active transmission, however, the consequences can be devastating.
The central lesson from decades of Ebola outbreaks remains unchanged: the sooner infections are identified, patients receive effective medical care and transmission chains are interrupted, the more lives can be saved.
This article is made and published by Aksel Kryhlmand, who may have used AI in the preparation.